Press Release

Nucleic Acid Amplification Testing Market to Grow with a CAGR of 11.56% through 2029F

The prevalence of infectious diseases, pandemic-driven demand, and a growing focus on point-of-care testing is expected to drive the Global Nucleic Acid Amplification Testing Market growth in the forecast period, 2025-2029.

 

According to TechSci Research report, “Nucleic Acid Amplification Testing Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Nucleic Acid Amplification Testing Market stood at USD 7.23 billion in 2023 and is anticipated to grow with a CAGR of 11.56% in the forecast period, 2025-2029. This can be attributed to the pandemic impact. The COVID-19 pandemic, in particular, has placed an unprecedented demand on diagnostic testing. The need for rapid and accurate testing methods to detect the SARS-CoV-2 virus has driven the development and adoption of NAAT techniques. This crisis has accelerated the growth of the NAAT market and highlighted the importance of investing in diagnostic capabilities.

NAAT technologies are invaluable in biobanking and research, allowing for the storage and analysis of genetic samples. As research in genetics and genomics continues to expand, the NAAT market will play a crucial role in supporting these efforts. Also, with the rise of RNA-based viruses like SARS-CoV-2, the demand for RNA-based diagnostics is increasing. The NAAT market will likely witness a surge in RNA-specific testing solutions, including novel techniques for detecting RNA viruses quickly and accurately.

           

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Nucleic Acid Amplification Testing Market

 

The market is experiencing growth driven by an increased demand for advanced rapid diagnostic solutions and higher research and development investments in the development of innovative biotechnological diagnostic techniques. The global prevalence of infectious diseases and the necessity for highly efficient testing options to effectively manage disease outbreaks have led to increased demand for various nucleic acid amplification testing technologies. The COVID-19 pandemic has heightened the need for swift and accurate testing methods, particularly nucleic acid amplification, to detect the SARS-CoV-2 virus. Major market players have responded by introducing new products, including tests based on isothermal nucleic acid amplification technology, to meet the elevated demand for rapid and point-of-care testing.

For example, in March 2020, Abbott Laboratories received Emergency Use Authorization (EUA) for its Abbott ID NOW COVID-19 test, capable of delivering positive results within five minutes and negative results within 13 minutes. Such strategic initiatives prompted by the pandemic are expected to stimulate market growth in the near future.

Nucleic acid amplification testing is widely utilized for its precise detection of target entities, primarily in the context of identifying infectious agents. This technique has been extensively explored for diagnostic applications in fields like cancer, personalized medicine, and forensics. Consequently, a wide range of applications for nucleic acid amplification testing is anticipated to drive market growth during the forecast period.

The emergence of infectious diseases, such as the Monkeypox virus, is creating new opportunities for market expansion. This is evident from the launch and regulatory approval of nucleic acid amplification test products for these diseases. For instance, in September 2022, Quest Diagnostics obtained Emergency Use Authorization (EUA) from the U.S. FDA for its Quest Monkeypox PCR test, which was introduced in July 2022. Similarly, in August 2022, Todos Medical Ltd. commercially launched its Monkeypox PCR-based test in the U.S. Consequently, these novel infections are poised to further expand market growth.

However, nucleic acid amplification methods, including polymerase chain reaction (PCR), are constrained by their dependence on thermal cycling and temperature control equipment, limiting the adoption of PCR technologies in point-of-care applications. This limitation could hinder the growth of PCR-based technologies and constrain market expansion in the near future.

The Global Nucleic Acid Amplification Testing Market is segmented into type, application, end use, regional distribution, and company.

The Isothermal Nucleic Acid Amplification Technology (INAAT) test segment is projected to witness rapid compound annual growth rate (CAGR) expansion during the forecast period in the Global Nucleic Acid Amplification Testing Market. This growth is due to several key factors: INAAT methods, such as Loop-Mediated Isothermal Amplification (LAMP) and Recombinase Polymerase Amplification (RPA), simplify the nucleic acid amplification process by eliminating the need for thermal cycling. This allows for faster results and makes the technology more suitable for point-of-care testing and use in resource-limited settings. The equipment required for INAAT is generally less expensive and less complex compared to traditional PCR machines. This cost advantage makes INAAT an attractive option for healthcare providers, particularly in developing regions where financial resources may be limited.

INAAT platforms are often portable and easy to use, enabling broader access to molecular diagnostics in remote and underserved areas. This portability facilitates on-site testing, which is critical for timely disease detection and management. INAAT is versatile and can be applied to various fields, including infectious disease diagnosis, food safety testing, and environmental monitoring. Its ability to rapidly detect a wide array of pathogens enhances its utility across different sectors. The increasing need for rapid and accurate diagnostic tests, especially in light of recent global health emergencies such as the COVID-19 pandemic, has driven the demand for efficient testing methods like INAAT. This technology's ability to deliver quick and reliable results makes it highly valuable in controlling and preventing disease outbreaks.

Based on end use, the central and reference laboratories category took the lead in terms of revenue share in 2023, primarily because of its broad range of testing services and its coverage across various healthcare settings. Additionally, government support in the form of initiatives is facilitating the expansion of testing capabilities for these laboratories. For example, in June 2022, the Department of Health and Human Services (HHS) extended the Monkeypox testing capacity to five laboratory companies, including Lab Corp., Quest Diagnostics, Mayo Clinic Laboratories, Aegis Science, and Sonic Healthcare.

Looking forward, during the forecast period from 2025 to 2029, the hospital sector is projected to experience the most rapid Compound Annual Growth Rate (CAGR). This growth is driven by the increasing global healthcare expenditure and the growing significance of nucleic acid amplification techniques in disease surveillance and the prevention of outbreaks. Similarly, the expansion of hospital testing capabilities following the COVID-19 pandemic and the availability of high-throughput testing technologies have the potential to significantly enhance market prospects for nucleic acid amplification testing.

 

Major companies operating in Global Nucleic Acid Amplification Testing Market are:

·         F Hoffmann-La Roche AG

·         Becton, Dickinson and Company

·         Danaher Corporation

·         Abbott Laboratories Inc

·         Illumina Inc

·         Siemens Healthineers AG

·         bioMérieux SA

·         Novartis AG

·         Bio-Rad Laboratories Inc

·         Seegene Inc 

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The Global Nucleic Acid Amplification Testing Market is poised for continued growth and innovation. The integration of digital technologies into NAAT is another significant trend. Digital PCR and next-generation sequencing (NGS) are becoming more prevalent due to their ability to provide high sensitivity, precision, and the ability to perform multiplexed assays. These technologies are transforming the way nucleic acid testing is conducted, enabling more detailed genetic analysis and more accurate detection of low-abundance targets. Additionally, the use of digital platforms for data analysis and interpretation is improving the efficiency and reliability of NAAT, making these tests more accessible and user-friendly.,” said Mr. Karan Chechi, Research Director, TechSci Research, a research-based management consulting firm.

Nucleic Acid Amplification Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Polymerase Chain Reaction (PCR) tests, Isothermal Nucleic Acid Amplification Technology (INAAT) tests, Ligase Chain Reaction (LCR) tests), By Application (Infectious disease testing, Oncology testing, Genetic & mitochondrial disease testing, Others), By End Use (Hospitals, Central and reference laboratories, Others), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Nucleic Acid Amplification Testing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Nucleic Acid Amplification Testing Market.

 

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com

 

Relevant News